Compare Ginkgo Bioworks Holdings Inc (DNA) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs M&T Bank Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while M&T Bank Corporation trades at $242.05 (market cap $35.42B). The key difference: M&T Bank Corporation is far larger — about 60× Ginkgo Bioworks Holdings Inc's market cap, and M&T Bank Corporation pays a 2.48% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MTB | |
|---|---|---|
Market Cap | $590.53M | $35.42B |
Sector | Health | Financials |
52-Week High | $16.14 | $242.55 |
52-Week Low | $5.48 | $178.63 |
Enterprise Value | $627.78M | — |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
M&T Bank Corporation (MTB) trades at $242.55, up 0.09% today, with a bullish technical signal supported by moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.18 exceeding expectations of $4.02. Revenue grew to $9.63B in 2025, with a net income margin of 29.59%. Recent news highlights Q2 2026 results announcement on July 15, 2026, with expectations of higher net interest income and loan growth.
Outlook remains positive due to strong profitability and dividend stability, but risks include elevated costs and net cash flow volatility. Analyst consensus is mixed with 29% buy ratings, though the price target of $242.72 suggests limited upside from current levels. Investors should weigh solid fundamentals against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
